Home LiteratureArticle Details
PMID: 24449346 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa.

Millares L, Ferrari R, Gallego M, Garcia-Nuñez M, Pérez-Brocal V, Espasa M, Pomares X, Monton C, Moya A, Monsó E

Abstract

The bronchial microbiome in severe COPD during stability and exacerbation in patients chronically colonised by Pseudomonas aeruginosa (PA), has not been defined. Our objective was to determine the characteristics of the bronchial microbiome of severe COPD patients colonised and not colonised by P. aeruginosa and its changes during exacerbation. COPD patients with severe disease and frequent exacerbations were categorised according to chronic colonisation by P. aeruginosa. Sputum samples were obtained in stability and exacerbation, cultured, and analysed by 16S rRNA gene amplification and pyrosequencing. Sixteen patients were included, 5 of them showing chronic colonisation by P. aeruginosa. Pseudomonas genus had significantly higher relative abundance in stable colonised patients (p = 0.019), but no significant differences in biodiversity parameters were found between the two groups (Shannon, 3 (2-4) vs 3 (2-3), p = 0.699; Chao1, 124 (77-159) vs 140 (115-163), p = 0.364). In PA-colonised patients bronchial microbiome changed to a microbiome similar to non-PA-colonised patients during exacerbations. An increase in the relative abundance over 20 % during exacerbation was found for Streptococcus, Pseudomonas, Moraxella, Haemophilus, Neisseria, Achromobacter and Corynebacterium genera, which include recognised potentially pathogenic microorganisms, in 13 patients colonised and not colonised by P. aeruginosa with paired samples. These increases were not identified by culture in 5 out of 13 participants (38.5 %). Stable COPD patients with severe disease and PA-colonised showed a similar biodiversity to non-PA-colonised patients, with a higher relative abundance of Pseudomonas genus in bronchial secretions. Exacerbation in severe COPD patients showed the same microbial pattern, independently of previous colonisation by P. aeruginosa.

MeSH Terms
Aged Aged, 80 and over Bronchi/microbiology Cluster Analysis Cohort Studies DNA, Bacterial/chemistry,genetics DNA, Ribosomal/chemistry,genetics Female Humans Male Microbiota Middle Aged Molecular Sequence Data Phylogeny Pulmonary Disease, Chronic Obstructive/microbiology RNA, Ribosomal, 16S/genetics Sequence Analysis, DNA Sputum/microbiology
Chemicals
DNA, Bacterial DNA, Ribosomal RNA, Ribosomal, 16S
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Millares L
Fundació Parc Taulí, Sabadell, Spain.
Ferrari R
Gallego M
Garcia-Nuñez M
Pérez-Brocal V
Espasa M
Pomares X
Monton C
Moya A
Monsó E
References (42)
42 references, click to expand
  1. Analysis of the lung microbiome in the "healthy" smoker and in COPD.
    PLoS One. 2011 Feb 22;6(2):e16384 PMID: 21364979
  2. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.
    Int J Chron Obstruct Pulmon Dis. 2011;6:449-56 PMID: 22003290
  3. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut.
    Appl Environ Microbiol. 1999 Nov;65(11):4799-807 PMID: 10543789
  4. Investigating the biological and clinical significance of human dysbioses.
    Trends Microbiol. 2011 Sep;19(9):427-34 PMID: 21775143
  5. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
    Ann Intern Med. 1987 Feb;106(2):196-204 PMID: 3492164
  6. The mathematical theory of communication. 1963.
    MD Comput. 1997 Jul-Aug;14(4):306-17 PMID: 9230594
  7. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.
    Chest. 1999 Jul;116(1):40-6 PMID: 10424501
  8. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing.
    Eur J Clin Microbiol Infect Dis. 2009 Sep;28(9):1151-4 PMID: 19449045
  9. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
    Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1498-505 PMID: 9603129
  10. Chapter 12: Human microbiome analysis.
    PLoS Comput Biol. 2012;8(12):e1002808 PMID: 23300406
  11. Topographical continuity of bacterial populations in the healthy human respiratory tract.
    Am J Respir Crit Care Med. 2011 Oct 15;184(8):957-63 PMID: 21680950
  12. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Clin Microbiol Infect. 2005 Sep;11(9):690-703 PMID: 16104983
  13. Pseudomonas aeruginosa in chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2008 Apr 15;177(8):853-60 PMID: 18202344
  14. Disordered microbial communities in asthmatic airways.
    PLoS One. 2010 Jan 05;5(1):e8578 PMID: 20052417
  15. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation.
    Adv Ther. 2008 Oct;25(10):1019-30 PMID: 18821068
  16. Culture enriched molecular profiling of the cystic fibrosis airway microbiome.
    PLoS One. 2011;6(7):e22702 PMID: 21829484
  17. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
    Pediatr Pulmonol. 2002 Aug;34(2):91-100 PMID: 12112774
  18. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease.
    J Infect Dis. 2009 Dec 15;200(12):1928-35 PMID: 19919307
  19. Therapeutic correction of bacterial dysbiosis discovered by molecular techniques.
    Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16413-4 PMID: 18948599
  20. Comparison of the respiratory microbiome in healthy nonsmokers and smokers.
    Am J Respir Crit Care Med. 2013 May 15;187(10):1067-75 PMID: 23491408
  21. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.
    Appl Environ Microbiol. 2009 Dec;75(23):7537-41 PMID: 19801464
  22. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis.
    Am J Med. 2000 Sep;109(4):288-95 PMID: 10996579
  23. The many faces of Pseudomonas aeruginosa in chronic obstructive pulmonary disease.
    Clin Infect Dis. 2008 Dec 15;47(12):1534-6 PMID: 19025364
  24. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
    Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55 PMID: 17507545
  25. Significance of the microbiome in obstructive lung disease.
    Thorax. 2012 May;67(5):456-63 PMID: 22318161
  26. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.
    Chest. 1998 Jun;113(6):1542-8 PMID: 9631791
  27. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.
    Gut. 2006 Feb;55(2):205-11 PMID: 16188921
  28. Guidelines for the management of adult lower respiratory tract infections.
    Eur Respir J. 2005 Dec;26(6):1138-80 PMID: 16319346
  29. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods.
    Microbiol Immunol. 2002;46(8):535-48 PMID: 12363017
  30. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.
    Respir Med. 1999 Jul;93(7):476-80 PMID: 10464834
  31. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
    N Engl J Med. 2002 Aug 15;347(7):465-71 PMID: 12181400
  32. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2013 Nov 15;188(10):1224-31 PMID: 23992479
  33. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study.
    Eur Respir J. 2009 Nov;34(5):1072-8 PMID: 19386694
  34. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research.
    Proc Am Thorac Soc. 2007 Oct 1;4(7):512-21 PMID: 17878463
  35. Metagenomic biomarker discovery and explanation.
    Genome Biol. 2011 Jun 24;12(6):R60 PMID: 21702898
  36. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.
    JAMA. 2002 Jun 12;287(22):2958-67 PMID: 12052125
  37. Pseudomonal infections in patients with COPD: epidemiology and management.
    Am J Respir Med. 2003;2(6):459-68 PMID: 14719985
  38. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
    J Infect Dis. 2001 Feb 1;183(3):444-52 PMID: 11133376
  39. QIIME allows analysis of high-throughput community sequencing data.
    Nat Methods. 2010 May;7(5):335-6 PMID: 20383131
  40. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery].
    Arch Bronconeumol. 2008 Nov;44(11):629-40 PMID: 19007570
  41. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease.
    Clin Infect Dis. 2008 Dec 15;47(12):1526-33 PMID: 18990062
  42. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease.
    Arch Intern Med. 2005 Apr 25;165(8):891-7 PMID: 15851640
Article Info
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Abbr.
Eur J Clin Microbiol Infect Dis
ISSN
1435-4373
Published
2014-07-00
Epub
2014-00-22
Pages
1101-11
Language
English
Region
Germany
NLM ID
8804297
PMCID
PMC4042013
Subset
IM
Databases
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com